The Life Sciences team represented eGenesis on its acquisition of the assets and operations of ICBiotec (“ICB”), one of the few companies in the U.S. with advanced cloning and large animal transgenic production capabilities integral to the xenotransplantation supply chain. Under the terms of the transaction, eGenesis will acquire ICB’s existing facilities, equipment, and land. ICB’s research and operations staff will continue as employees of a wholly-owned subsidiary of eGenesis. The acquisition will provide eGenesis with full control of its xeno-organ supply chain. Financial terms for the transaction were not disclosed.
eGenesis’ goal is to advance the field of transplantation and make available safe and reliable xeno organs, tissues, and cells to patients in need. eGenesis uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date.
The Goodwin transaction team was led by Arthur McGivern, Jason Breen, Catherine Magazu, and Brittany Morreale.
For additional background on the acquisition, please read the press release.